This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
Genentech’s ocular implant drugdeliverysystem for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port deliverysystem into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
at Northwestern University—has developed novel technology with the potential to change the future of drugdelivery. A team of scientists—led by Yamin Zhang, Ph.D., and Colin Franz, MD, Ph.D., at Shirley Ryan AbilityLab and John Rogers, Ph.D.,
Ceapro has extended a partnership underway to carry out a further research project with McMaster University for developing an inhalable immuno-therapeutic/-prophylactic for Covid-19-induced lung fibrosis. This project is intended to develop therapies for people suffering from Covid-19’s long-term effects.
The purpose of writing this review on floating drugdeliverysystems (FDDS) was to The recent developments of FDDS including the physiological and formulation variables affecting gastric retention, approaches to design single-unit and multiple-unit floating systems, and their classification and formulation aspects are covered in detail.
Interestingly, over the past few years, drugdevelopers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
Programmable Oligonucleotide DeliverySystem (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.
Liposomes are concentric bilayer vesicles, which were first developed by Bangham and his colleagues in 1961. They are highly efficient having high drug entrapment capacity. Due to their size, hydrophobic and lipophilic character they are most widely used vehicles for drugdelivery.
In a promising advancement, scientists from the University of North Carolina at Chapel Hill and Emory University have developed a novel drugdeliverysystem using synthetic amyloid beta (AÎ) peptides.
CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drugdeliverysystems for newly developed biologics along with medical and diagnostic products.
Elyxyb is a prescription nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine treatment in adult patients with or without aura. It is formulated using a self-micro-emulsifying drugdeliverysystem that improves the drug’s bioavailability and solubility.
Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drugdeliverysystems and medical devices.
Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. it is administered through intravenous route.
Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is administered by parenteral route.
–(BUSINESS WIRE)–Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases as well as sustained-release drugdeliverysystems, announced it has been awarded a $1.0-million million grant to develop a long-term bioerodible birth control implant.
Presently, outsourcing of liposomes development and manufacturing related services has become a popular practice. Drugdevelopers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise.
The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, business development managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.
Available in a range of sizes, the company’s proprietary rubber compounds such as FM257 and FM457 are used in drugdeliverysystems by some of the world’s largest pharmaceutical organisations. As such, NeoFlex plungers are ideal for highly sensitive, large molecule drugs. A new challenge .
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. Langer’s engineering lab was instrumental in the development of these lipid nanoparticles, playing into his role in co-founding Moderna.
Innovation S-curve for Internet of Things in the pharmaceutical industry Nanoparticles for drugdelivery is a key innovation A nanoparticle is a small particle ranging in size from 1 to 100 nanometres. Nanoparticles are used as novel drugdeliverysystems to deliver drugs to specific tissues and to provide controlled release therapy.
The companies allege Moderna’s vaccine uses their technology for a drug-deliverysystem without permission. Citing The single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the Omicron-tailored Covid-19 booster shot developed by both companies.
SHL Medical is a world-leading solutions provider for advanced drugdeliverysystems with a unified purpose to further enable patient independence. The Charleston Regional Development Alliance (CRDA) is supporting SHL Medical by facilitating valuable connections to best-in-class service providers in the area.
Developed and manufactured by: 3M DrugDeliverySystems, Northridge, CA 91324, U.S.A. More specifically, different aspects of its production occur in three countries. Here’s what the label says: Manufactured for Par Pharmaceutical, Chestnut Ridge, NY 10977, U.S.A. Albuterol Sulfate (active ingred.)
However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.
In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drugdeliverysystems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to the long-acting drugdelivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
The VTT Technical Research Centre of Finland has addressed this issue by developing a fully recyclable, modular ECG patch constructed from VTT’s novel cellulose e-skin material. This device is designed such that the electronic components can be easily removed and reused. How Can VTT’s ECG Patch Impact the Healthcare Industry?
In order to promote the use of exosomes in various therapeutic applications including targeted drugdelivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Want additional details on the pipeline?
Conjugation with a Variety of Molecular Conjugates and Labels The combination of the conjugates / labels with molecules ( proteins, peptides, antibodies and small molecules ) is being used abundantly for several applications, ranging from therapeutics and diagnostics to isolation and characterization of drugdeliverysystems.
However, certain biological targets have long eluded drugdevelopment efforts. Advances in drug discovery and development technologies / platforms have increased the likelihood of targeting a number of the aforementioned types of biological targets.
Register for this free webinar to learn the best practices to successfully incorporate 2022 ISO 11608 methodology to mitigate risk and accelerate time to market in combination product development. The FDA’s Innovation Challenge 2 is centered on developing strategies to lower EtO emissions.
Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. Oral Protein / Peptide-based Drugs. Web: [link].
Healthcare Technology commonly known as ‘Healthtech’ is the usage of technology developed to aid all healthcare related activities or any software or tool specifically designed to provide assistance to healthcare professionals, administrators, managers in the most effortless way possible. DrugDevelopment. Diagnostics.
Outsourcing offers several benefits to the developers including cost saving opportunities, increased operational efficiencies, expedited time-to-market, access to advanced capabilities and technologies, validated quality control setup, flexibility, risk sharing and, in several cases, regulatory support. Our Social Media Platform. Web: [link].
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics. Web: [link].
The company developingdrug product through such an intense process, use to consider container closure system only for packaging of the product. [1] In earlier times, container closure integrity testing was not regarded as an essential step in the process of manufacturing. Our Social Media Platform. Web: [link]. Twitter: [link].
The integration of the blue ocean strategy in healthcare landscape, often known as blue ocean therapy, and its application in medical product development, such as blue ocean medical products, is the silver lining that can revolutionize the industry. This strategy is not a silver bullet; it’s a calculated voyage into uncharted waters.
The FTC expressed concern that patent listings that do not meet the statutory criteria undermine the competitive process, may disincentivize investment in developing generic and follow-on products, and reduce patient access to more affordable drugs thereby increasing costs to the healthcare system.
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. million adults in the United States.
CNS drugs treat a range of neurologic and psychiatric disorders, such as psychosis, depression, Parkinson’s disease, multiple sclerosis and epilepsy. Direct CNS administration techniques facilitate drugdelivery to the brain to treat neurological disorders and these approaches are vital for CNS targets.
Shafi Khan , Burkhan World’s VP of Business Development stated, “Burkhan is honoured to have partnered up with Vivera in supporting its efforts globally in the medical supply sector. With management expertise in hospitality and finance, the Burkhan World Group of Companies, based in Washington D.C. ,
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content